Payment overview · 2025
General Payments
$150.18
8 reported records · 5 companies
Healthcare provider profile · identity verified
Russell Eric Hatley, MD
Allopathic & Osteopathic Physicians|Family Medicine · EL DORADO, AR · NPI 1932194974
Verified facts
What the public records show
CMS Open Payments records show Russell Eric Hatley, MD received $150.18 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.06 | 40.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.79 | 25.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.00 | 14.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.43 | 10.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.90 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.18 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.06 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.06 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.79 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
396 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 110 |
| Eliquis | Apixaban | 396 | 33 |
| Potassium Chloride | Potassium Chloride | 368 | 80 |
| Furosemide | Furosemide | 334 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 62 |
| Gabapentin | Gabapentin | 276 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 52 |
| Carvedilol | Carvedilol | 219 | 46 |
| Memantine Hcl | Memantine Hcl | 181 | 33 |
| Omeprazole | Omeprazole | 181 | 45 |
| Sertraline Hcl | Sertraline Hcl | 181 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 42 |
| Allopurinol | Allopurinol | 169 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 160 | 33 |
| Lisinopril | Lisinopril | 157 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 42 |
| Simvastatin | Simvastatin | 141 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 41 |
| Losartan Potassium | Losartan Potassium | 131 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 33 |
| Metformin Hcl Er | Metformin Hcl | 123 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 25 |
| Mirtazapine | Mirtazapine | 118 | 22 |
| Prednisone | Prednisone | 116 | 42 |
| Glimepiride | Glimepiride | 115 | 29 |
| Januvia | Sitagliptin Phosphate | 114 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 24 |
| Donepezil Hcl | Donepezil Hcl | 111 | 16 |
| Metformin Hcl | Metformin Hcl | 105 | 24 |
| Trazodone Hcl | Trazodone Hcl | 105 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 20 |
| Celecoxib | Celecoxib | 99 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 23 |
| Levetiracetam | Levetiracetam | 91 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 15 |
| Latanoprost | Latanoprost | 88 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 86 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 21 |
| Ezetimibe | Ezetimibe | 72 | 21 |
| Digoxin | Digoxin | 70 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 24 |
| Alendronate Sodium | Alendronate Sodium | 64 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 15 |
| Tramadol Hcl | Tramadol Hcl | 63 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 18 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Glipizide | Glipizide | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Etodolac | Etodolac | 48 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 11 |
| Nifedipine Er | Nifedipine | 44 | 12 |
| Spironolactone | Spironolactone | 44 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 28 |
| Famotidine | Famotidine | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | 11 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 26 |
| Budesonide | Budesonide | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 20 |
| Temazepam | Temazepam | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 14 |
| Colchicine | Colchicine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 11 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Bimatoprost | Bimatoprost | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.18 · 8 records | ABBVIE INC. | ABRYSVO, COMIRNATY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error